Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials - Suleiman, Ahmed Abbas; Lin, Chih-Wei; Liu, Wei; Eckert, Doerthe; Mensing, Sven; Burroughs, Margaret; Kato, Koji; Chayama, Kazuaki; Kumada, Hiromitsu; Oberoi, Rajneet K (Journal of clinical pharmacology, 2020)
Keywords: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Aminoisobutyric Acids - administration & dosage; Aminoisobutyric Acids - adverse effects; Aminoisobutyric Acids - pharmacokinetics; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - pharmacokinetics; Area Under Curve; Benzimidazoles - administration & dosage; Benzimidazoles - adverse effects; Benzimidazoles - pharmacokinetics; Biological Availability; Body Weight; Cyclopropanes - administration & dosage; Cyclopropanes - adverse effects; Cyclopropanes - pharmacokinetics; Drug Administration Schedule; Drug Combinations; Female; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; Humans; Japan; Lactams, Macrocyclic - administration & dosage; Lactams, Macrocyclic - adverse effects; Lactams, Macrocyclic - pharmacokinetics; Leucine - administration & dosage; Leucine - adverse effects; Leucine - analogs & derivatives; Leucine - pharmacokinetics; Liver Cirrhosis - genetics; Liver Cirrhosis - metabolism; Male; Middle Aged; Models, Biological; Proline - administration & dosage; Proline - adverse effects; Proline - analogs & derivatives; Proline - pharmacokinetics; Quinoxalines - administration & dosage; Quinoxalines - adverse effects; Quinoxalines - pharmacokinetics; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - pharmacokinetics; Young Adult; Japan; hepatitis C virus; glecaprevir/pibrentasvir; Japanese; direct-acting antivirals; population pharmacokinetics